现代新MRNA流感疫苗显示,保护率比标准疫苗高26.6%,特别是在老年人中。 Moderna's new mRNA flu vaccine shows 26.6% better protection than standard vaccines, notably in older adults.

现代新MRNA流感疫苗MRNA-1010在第三阶段试验中取得了显著成果,比标准流感疫苗多提供26.6%的流感防疫保护。 Moderna's new mRNA flu vaccine, mRNA-1010, showed strong results in a Phase 3 trial, providing 26.6% more protection against the flu than a standard flu vaccine. 它在65岁及65岁以上的成年人中特别有效,改善了27.4%。 It was especially effective in adults 65 and older, with a 27.4% improvement. 疫苗在不同年龄组和健康状况中有效。 The vaccine was effective across different age groups and health conditions. 现代计划提交完整的审判数据,并将结果发表在同行评审的期刊上。 Moderna plans to present the full trial data and publish the results in a peer-reviewed journal.